Cebiotex, member of CataloniaBio & HealthTech, is working on a drug that consists of a membrane made from biodegradable fibers that releases a natural molecule with a high chemotherapeutic capacity and can be implanted after tumor extraction, on the surgical bed. It can be used in the treatment of localized solid tumours.
The purpose of local drug release is to achieve high concentrations of active ingredients in the area where the release device is placed and, thus, avoid systemic toxicity and increase the drug's effectiveness against possible tumour remnants.
This pharmaceutical product is very innovative and unique in the market because they have managed to make it compatible with chemotherapy. The technology will allow for the development of new drugs and entry into other oncological indications, such as the treatment of pancreatic cancer or brain tumours.
The fact that this membrane can be implanted in the operated area after tumour extraction prevents the viability of cancer cells that may have remained after surgery. The drug is being developed at the Hospital de Sant Pau (Barcelona), Vall d'Hebron (Barcelona), both members of CataloniaBio & HealthTech, Hospital de La Fe (Valencia), Fundación Jiménez Díaz (Madrid), and Hospital Gregorio Marañón (Madrid).
Cebiotex wants to ensure that the project maintains a paediatric focus since it was born with the aim of finding solutions for childhood cancer. For now, the funds will allow them to continue clinical trials with adult patients with soft tissue sarcoma, and later, clinical trials can be initiated with paediatric patients.
Comments